CN Patent

CN117881416A — 用于治疗儿童的骨骼发育不良的c型利钠肽变体

Assigned to Biomarin Pharmaceutical Inc · Expires 2024-04-12 · 2y expired

What this patent protects

本公开提供了C型利钠肽(CNP)变体用于治疗儿童骨骼发育不良并且改善骨骼发育不良的一种或多种症状的用途，如长骨生长或生长速度，以及在具有骨骼发育不良和/或CNP相关症状或组分的其它病症中的用途。

USPTO Abstract

本公开提供了C型利钠肽(CNP)变体用于治疗儿童骨骼发育不良并且改善骨骼发育不良的一种或多种症状的用途，如长骨生长或生长速度，以及在具有骨骼发育不良和/或CNP相关症状或组分的其它病症中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN117881416A
Jurisdiction
CN
Classification
—
Expires
2024-04-12
Drug substance claim
No
Drug product claim
No
Assignee
Biomarin Pharmaceutical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.